AN2 Therapeutics (ANTX) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Jyong Biotech (MENS) over the past year, gaining 254.8% versus a loss of 96.1%. AN2 Therapeutics is the larger company by market cap ($166.0 million vs $159.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | MENS |
|---|---|---|
| Share price | $4.40 | $2.10 |
| Market cap | $166.04M | $159.66M |
| 1-day change | -5.98% | 0.00% |
| YTD return | +285.96% | -46.84% |
| 1-year return | +254.84% | -96.12% |
| EPS (TTM) | $-1.05 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $63.00 |
| 52-week low | $1.00 | $1.43 |
| Distance from 52-week high | -38.80% | -96.67% |
| Analyst consensus | none | — |
| Avg. price target upside | +104.55% | — |
| Average volume | 240.21K | 45.61K |
| Shares outstanding | 37.74M | 74.23M |
| Employees | 21 | 27 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed MENS by 351.0 percentage points over the past year.
- The two companies sit in different sectors: AN2 Therapeutics in Healthcare and Jyong Biotech in Health Care.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Healthcare · Biotechnology · 21 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
ANTX vs MENS FAQ
Which is bigger, AN2 Therapeutics or Jyong Biotech?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $166.04M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, ANTX or MENS?
ANTX returned +254.84% over the past 12 months, compared with -96.12% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Jyong Biotech in the same industry?
No. AN2 Therapeutics is in the Healthcare sector, while Jyong Biotech is in Health Care.